TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06971614: A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Sponsor: ImmVira Pharma Co. Ltd · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,903,200

Rescue Site Savings

+$7,207,200

Unlock Full NCT06971614 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06971614 Rescue Dossier →